Sign in

    Jesse Silveira

    Research Analyst at Spirit of the Coast Analytics

    Jesse Silveira is an analyst at Spirit of the Coast Analytics, specializing in in-depth equity research and fundamental analysis across emerging sectors. He covers a diversified slate of public companies, providing investment recommendations backed by robust performance metrics, although precise rankings and return figures are not publicly documented. Silveira began his analyst career prior to joining Spirit of the Coast Analytics but detailed previous employment history and major career milestones have not been disclosed in available records. His professional credentials and regulatory licenses are not currently listed in public databases, and there is no record of FINRA registration or notable industry recognitions at this time.

    Jesse Silveira's questions to ANAVEX LIFE SCIENCES (AVXL) leadership

    Jesse Silveira's questions to ANAVEX LIFE SCIENCES (AVXL) leadership • Q3 2025

    Question

    Jesse Silveira of Spirit of the Coast Analytics asked about the theoretical use of CRISPR technology to enhance blarcamesine's efficacy, the company's plans for an Alzheimer's prevention trial, and the strategic objectives behind retaining a lobbying firm and engaging with policymakers. He also inquired about Anavex's interest in the FDA's new accelerated approval voucher program.

    Answer

    President & CEO Dr. Christopher Missling acknowledged that CRISPR is theoretically possible but stated it's largely unnecessary as most patients have a functional sigma-1 gene. He confirmed Anavex plans a preventative trial based on positive preclinical data but noted it is resource-dependent and will follow the initial drug launch. Regarding lobbying, Dr. Missling described it as a standard industry practice to raise awareness and educate policymakers on the unmet needs in Alzheimer's disease. He affirmed the company's strong interest in the FDA's accelerated voucher program, viewing it as independent of any EMA decisions.

    Ask Fintool Equity Research AI

    Jesse Silveira's questions to ANAVEX LIFE SCIENCES (AVXL) leadership • Q3 2025

    Question

    Jesse Silveira of Spirit of the Coast Analytics inquired about the theoretical use of CRISPR technology to enhance blarcamesine's efficacy, plans for an Alzheimer's prevention trial, the strategic objectives of engaging with lobbyists, and the company's interest in the FDA's accelerated approval voucher program.

    Answer

    President & CEO Dr. Christopher Missling responded that while CRISPR is theoretically possible, it's not necessary for the vast majority of patients who have a functional sigma-1 gene. He confirmed plans for a preventative trial, pending resources, and explained that lobbying efforts are for raising awareness among policymakers. Dr. Missling affirmed the company's strong interest in the FDA's accelerated voucher program, stating it is independent of any EMA decision.

    Ask Fintool Equity Research AI